The FDA determined the pulsed light system to be substantially equivalent, clearing its path to the market as a Class II device.
Lumenis Be, Ltd. has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its SmartIPL_NI System, designated under product code GEX. The agency’s decision, issued on September 19, 2026, found the device to be substantially equivalent to previously cleared technologies.
The SmartIPL_NI System, a Class II medical device, was cleared through the Traditional 510(k) pathway, indicating a standard review process for devices demonstrating substantial equivalence to a predicate device. The clearance allows Lumenis Be to market the system in the United States, positioning it within the general and plastic surgery advisory committee's purview, which typically includes devices for aesthetic and therapeutic applications involving skin.
Regulatory Context and Device Classification
The FDA's decision was based on a Summary statement, meaning the agency assessed the provided information, including performance data and comparisons to predicate devices, to conclude substantial equivalence. The regulation number governing such devices is 878.4810, which pertains to Light-based Laser and Pulsed Light Surgical Instruments for general surgical and aesthetic use.
The Class II designation indicates that the device carries a moderate risk and requires general controls, along with special controls, to assure its safety and effectiveness. These special controls often involve performance standards, post-market surveillance, or specific labeling requirements, though the precise nature for the SmartIPL_NI System is not detailed in the public clearance record.
The substantial equivalence determination signifies the FDA's confidence that the device performs as intended without raising new questions of safety or effectiveness compared to existing market options.
Market Implications and Unspecified Details
While the FDA clearance enables market access, specific clinical indications, pricing, and availability details for the SmartIPL_NI System have not been publicly disclosed by Lumenis Be, Ltd. The company has not yet released information regarding the device's specific applications or its commercial rollout strategy following this regulatory milestone. The competitive landscape for pulsed light systems is established, suggesting Lumenis Be will be entering a market with existing solutions.
Further information regarding the device's clinical performance, user interface, or technological advancements beyond its regulatory classification awaits company disclosure. The clearance document itself provides no details on how SmartIPL_NI differs from or improves upon existing GEX-coded devices.
